High-Dose IV Vitamin C as an Oncology Adjunct

What is actually established

Intravenous administration is a routine, well-understood medical procedure, and giving ascorbate (vitamin C) intravenously is what makes this idea pharmacologically different from taking vitamin C tablets. Oral vitamin C is tightly capped by gut absorption and renal clearance, so plasma levels plateau at a modest ceiling no matter the dose swallowed. Bypassing the gut with an IV infusion can push plasma ascorbate concentrations tens to hundreds of times higher, into a range that laboratory and animal studies suggest may be selectively toxic to some cancer cell lines while sparing normal cells. That pharmacokinetic fact is well established.

What is not established by that pharmacokinetic fact alone is that reaching those plasma levels in a person with cancer changes anything that matters clinically, such as tumor response, progression-free survival, or how long someone lives. A mechanism that is plausible in a petri dish or a mouse does not automatically translate into a benefit in human patients receiving real-world chemotherapy regimens, and the honest answer is that this translation step is exactly what remains unproven.

What the evidence for this specific use actually shows

The main human evidence comes from a small Phase I/II randomized, placebo-controlled trial in women with newly diagnosed stage III or IV ovarian cancer, in which patients received carboplatin and paclitaxel with or without adjunctive high-dose IV ascorbate. In the observational extension of that trial (27 patients total), the group receiving IV ascorbate alongside chemotherapy showed an average 8.75-month increase in progression-free survival and experienced fewer chemotherapy-related toxicities than the chemotherapy-alone group.[1]

A 2018 systematic review pooled the available clinical trial evidence on IV ascorbate in cancer, covering 23 trials and 385 patients across many cancer types. It concluded that IV ascorbate appears safe across the cancer populations studied, but that only one of those trials (the ovarian cancer study above) showed a survival signal, and the field as a whole lacks high-quality, placebo-controlled randomized trials. Most of the included studies were small, single-arm, or uncontrolled, which limits how much weight any single positive finding can carry.[2]

The trap: a promising small signal is not proof

It is tempting to read "8.75 months longer progression-free survival" and treat it as settled. It is not. The trial that produced that number was a single-site study of 27 patients, not powered or designed to reliably detect a survival benefit, and progression-free survival in a trial this small can be moved by chance, by imbalances between the two small groups, or by factors unrelated to the vitamin C itself. A result like this is a legitimate reason to fund a larger confirmatory trial. It is not, on its own, a reason to describe IV vitamin C as an effective cancer treatment.[1]

What remains uncertain

The systematic review is explicit that only one of 23 identified trials showed a survival-related benefit, and that trial has not been replicated in an independent, larger, multi-site cohort. No Phase III trial has confirmed a progression-free or overall survival benefit for IV ascorbate as an adjunct to chemotherapy in ovarian cancer or any other tumor type. Optimal dosing, which patients might benefit most, and whether benefits seen in ovarian cancer generalize to other cancers are all open questions.[2]

Safety also has real boundaries that a review like this should not gloss over. High-dose IV ascorbate is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency because it can trigger severe hemolysis, and it requires caution in patients with impaired kidney function or a history of oxalate kidney stones, since ascorbate is metabolized to oxalate. These are established safety considerations for the infusion itself, independent of whether it helps against cancer, and they are why screening and physician oversight matter regardless of how promising the oncology data eventually turns out to be.

What this means for you

AION does not offer IV vitamin C as a cancer treatment and does not position it as an alternative to chemotherapy, surgery, or radiation. Where a patient already under active oncology care asks about it as an adjunct, our physicians treat it as an emerging, adjunctive option worth an honest conversation, not a therapy with proven survival benefit, and any decision is made in coordination with the patient's treating oncologist rather than in place of that relationship.

Diagnostics come before any infusion. That means confirming G6PD status, kidney function, and relevant labs before high-dose ascorbate is considered, because the safety profile depends on knowing those numbers, not assuming them. There is no fixed AION protocol dose or schedule for this indication, because the evidence itself has not defined one; what a physician recommends, if anything, depends on the individual patient's diagnosis, treatment plan, and lab results, reviewed case by case.